###### Strength and limitations in this study

-   The model may be appropriate for most low-income and middle-income countries because it is simple, does not require sophisticated statistical software nor huge amounts of specific data.

-   Not all relevant risk factors, such as physical inactivity, were included in the current model. Body mass index was used as a measure of obesity and finally the limited data available to estimate obesity trends for the Palestinian population.

-   The model can provide estimates for future diabetes prevalence which can inform policy using different intervention scenarios that can target the specific risk factors.

Introduction {#s1}
============

The International Diabetes Federation (IDF) suggested that there will be approximately 365 million people with diabetes worldwide in 2011. The MENA (Middle East and North Africa) region will have the highest prevalence of diabetes (12.5%) and the second largest proportional increase in the number of people with diabetes (85 million).[@R1] However, this predicted increase was mainly based on demographic changes and the assumption that urbanisation is a satisfactory proxy for risk factors such as obesity, smoking and physical activity.[@R2]

In Palestine, a few epidemiological studies have focused on non-communicable diseases including diabetes.[@R3] Most studies were cross-sectional in nature and provided estimates of the current prevalence for diabetes and obesity. However, the estimates of future prevalence which are urgently needed for proper planning are not available. Furthermore, the estimates reported by the IDF and the Global Burden of Disease study are broad and do not apply specifically to the Palestinian context.[@R1] [@R2] Thus, this paper aims to provide estimates of future diabetes prevalence in the West Bank, occupied Palestinian territory (oPt), and offer a modelling platform for policy decision-making.

Methods {#s2}
=======

The model integrates information on population, obesity and smoking trends at a given point of time to estimate diabetes prevalence in the future using a Markov model. The model is implemented in MS Excel and can accommodate different diabetes definitions.

We assume that the population can be divided into several pools: diabetes mellitus, obese, smoker and 'healthy' (eg, non-obese, non-smokers and people without diabetes). A proportion of the population in each pool moves through pathways to other states.

Population demographic trends are used to inform the relative size of the 'starting states', and transition probabilities are used to estimate the proportion of persons moving from the starting states to the diabetes and death states. There are two 'absorbing states': diabetes mellitus (DM)-related death and non-DM-related deaths. In this way, mortality competing risks are modelled. Potential overlaps between the healthy, obese and smoking groups are managed by calculating the conditional probabilities of membership.

Data needed {#s2a}
-----------

The model requires data by 10-year age and gender bands, starting at 25, ending 75+. Data needed for the initial year include population size and age distribution, diabetes prevalence, obesity prevalence, smoking prevalence and total mortality. Data needed for subsequent years for forecasting purposes include population projections, obesity and smoking trends. Data needed for incidence calculation include diabetes prevalence, total mortality and case-fatality. The sources of data used for trend and validation are listed in [table 1](#BMJOPEN2013003558TB1){ref-type="table"}. The Palestinian Demographic and Health Surveys and Ministry of Health Information Centre were the main sources of data used. The use of these secondary data was not needed.

###### 

Population and prevalence of diabetes, obesity and smoking prevalence for the starting year 2000

  2000                Population   Diabetes prevalence   Obesity prevalence   Smoking prevalence
  ------------------- ------------ --------------------- -------------------- --------------------
  Men (n=336 965)                                                             
   25--34             138 888      0.0133                0.159                0.594
   35--44             92 050       0.0871                0.195                0.561
   45--54             46 207       0.1516                0.353                0.525
   55--64             28 582       0.2451                0.324                0.422
   65--74             19 508       0.2467                0.298                0.331
   75+                11 730       0.1774                0.268                0.331
  Women (n=343 260)                                                           
   25--34             133 095      0.0052                0.213                0.041
   35--44             86 979       0.0386                0.401                0.071
   45--54             47 457       0.1522                0.564                0.064
   55--64             36 124       0.2833                0.602                0.054
   65--74             25 670       0.3294                0.432                0.033
   75+                13 935       0.3696                0.354                0.033

Diabetes incidence and specific mortality were estimated using the methods developed by Barendregt *et al*.[@R4] The methods for diabetes incidence and specific mortality are described in the technical appendix. Diabetes incidence, case-fatality and mortality stratified by age and sex were calculated using DISMOD programme based on three inputs with the assumption that these parameters are constant over time. However, this was taken into account when calculating the incidence parameter using trends in DISMOD: first diabetes prevalence for the year 2004 obtained from the Palestinian Demographic Health Survey, diabetes mellitus remission rate which was assumed 0 and diabetes mellitus relative risk (RR) for mortality which was estimated as proposed by Barendregt *et al*,[@R4] and based on the usual RR for mortality. The formula is

Model validation {#s2b}
----------------

Model validation is an important aspect of any modelling exercise, frequently overlooked.

We developed a model for the West Bank, oPt, over the period 2000--2020. During that period, subsequent surveys were conducted in DHS 2004, PFHS 2006, PFHS 2010, Stepwise Survey 2010 and we compared the model outputs with the observed prevalence estimates.

Sensitivity analysis {#s2c}
--------------------

We used the analysis of the extremes method (Briggs), consisting of running the model with all parameters set to a minimum and maximum realistic values. This is a very conservative approach, but allows a more transparent understanding of the weight of each parameter regarding model outcomes.

Policy scenarios {#s2d}
----------------

Since there are no current targets for adult obesity at the national level or for the West Bank, and since obesity is increasing and is predicted to continue to increase, we used a Mediterranean country, Turkey targets (scenario 1), WHO targets (scenario 4) and WHO regional targets (scenario 5). Further we proposed two targets which might be feasible (scenario 2) and ideal (scenario 3). These targets are set for population-based prevention.

  'What if' policy questions                                                                                                                     Reference
  ---------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Given a 2010 baseline: What will be the impact of a 5% relative reduction in obesity prevalence by 2015 on diabetes burden in the West Bank?   Ministry of Health, Turkey[@R5]
  What will be the impact of a 5% relative reduction in obesity prevalence by 2020 on diabetes burden in the West Bank?                          Assumption
  What will be the impact of a 10% relative reduction in obesity prevalence by 2020 on diabetes burden in the West Bank?                         Assumption
  What will be the impact of halting the rise in obesity prevalence (15%) by 2020 on diabetes burden in the West Bank?                           WHO[@R6]
  What will be the impact of 35% relative reduction in obesity prevalence by 2020 (baseline 2010) on diabetes burden in the West Bank?           WHO-EMRO

Results {#s3}
=======

Population characteristics at starting point {#s3a}
--------------------------------------------

The prevalence of diabetes among the Palestinian population aged 25 and above, living in the West Bank in the year 2000 was 9.1% for men and 10.2% for women. The risk factors included in the study were obesity and smoking ([table 2](#BMJOPEN2013003558TB2){ref-type="table"}). Obesity is a common risk factor among the Palestinian population with 22.1% prevalence among men and 37.2% among women. Smoking prevalence was very high among men (53.7%) but very low among women (5.2%).

###### 

Prevalence of diabetes and the number of people with diabetes estimated for the period 2000 and 2030

             Baseline                   5% Obese reduction in 5 years   WHO target to halt obesity prevalence (15% in 10 years)   WHO-EMRO 35% obese reduction in 10 years   5% Obese reduction in 10 years   10% Obese reduction in 10 years                                                                                                                                                                                                 
  ---------- -------------------------- ------------------------------- --------------------------------------------------------- ------------------------------------------ -------------------------------- --------------------------------- ------------------------------ -------------------------- ------------------------------ -------------------------- ------------------------------ --------- --------- -- --------- --------- --
  2015       215 042                    211 219                         3823                                                      210 278                                    4764                             206 673                           8369                           212 176                    2866                           211 219                    3823                                                                      
  Min--Max   148 627                    292 814                         146 443                                                   286 159                                                                     146 443                           286 159                                                   146 443                        286 159                                                   146 443   146 443      146 443   286 159   
  2020       289 103                    277 317                         11 786                                                    273 902                                    15 201                           261 510                           27 593                         280 866                    8236                           277 317                    11 786                                                                    
  Min--Max   207 052                    398 856                         198 010                                                   372 107                                                                     198 010                           372 107                                                   198 010                        372 107                                                   198 010   198 010      198 010   372 107   
  2025       365 597                    342 837                         22 760                                                    335 582                                    30 015                           310 687                           54 910                         350 552                    15 045                         342 837                    22 760                                                                    
  Min--Max   272 271                    515 599                         251 930                                                   456 947                                                                     251 930                           456 947                                                   251 930                        456 947                                                   251 930   251 930      251 930   456 947   
  2030       444 296                    407 308                         36 988                                                    394 879                                    49 416                           354 622                           89 674                         420 837                    23 458                         407 308                    36 988                                                                    
  Min--Max   342 629                    641 053                         307 266                                                   541 257                                                                     307 266                           541 257                                                   307 266                        541 257                                                   307 266   307 266      307 266   541 257   
                                                                                                                                                                                                                                                                                                                                                                                                                                              
             **Estimated prevalence**   **Estimated prevalence**        **Per centage of reduction**                              **Estimated prevalence**                   **Per centage of reduction**     **Estimated prevalence**          **Per centage of reduction**   **Estimated Prevalence**   **Per centage of reduction**   **Estimated Prevalence**   **Per centage of reduction**                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2015       18.4                       18.1                            1.8                                                       18.0                                       2.2                              17.7                              3.9                            18.2                       1.3                            18.1                       1.8                                                                       
  Min--Max   15.9                       20.9                            15.7                                                      20.5                                                                        15.7                              20.5                                                      15.7%                          20.5                                                      15.7      20.5         15.7      20.5      
  2020       20.6                       19.8                            4.1                                                       19.6                                       5.3                              18.7                              9.5                            20.1                       2.8                            19.8                       4.1                                                                       
  Min--Max   18.5                       23.7                            17.7                                                      22.1                                                                        17.7                              22.1                                                      17.7                           22.1                                                      17.7      22.1         17.7      22.1      
  2025       21.6                       20.2                            6.2                                                       19.8                                       8.2                              18.3                              15.0                           20.7                       4.1                            20.2                       6.2                                                                       
  Min--Max   20.1                       25.3                            18.6                                                      22.5                                                                        18.6                              22.5                                                      18.6                           22.5                                                      18.6      22.5         18.6      22.5      
  2030       21.5                       19.7                            8.3                                                       19.1                                       11.1                             17.1                              20.2                           20.3                       5.3                            19.7                       8.3                                                                       
  Min--Max   20.7                       25.8                            18.5                                                      21.8                                                                        18.5                              21.8                           2.2                        18.5                           21.8                                                      18.5      21.8         18.5      21.8      

Risk factor trends 2000--2030 {#s3b}
-----------------------------

The changes in obesity and smoking prevalence were assumed to be linear with various degrees between men and women and within different age groups. Obesity prevalence was higher among women compared with men at 2000 with the highest prevalence observed for the ages 45--54 years and 55--64 years. The prevalence reached plateau at the age of 55--64 years and 65--74 years for women and 65--74 years for men. Obesity prevalence increased in men and women while smoking prevalence decreased in the period 2000--2030. The decrease in smoking prevalence varied between the age groups with a faster decrease among the older age groups.

Obesity prevalence has increased from 22.1% in men and 37.2% in women in 2000 to 29.1% in men and 39.6% women in 2010. Smoking trends decreased over 10 years period. Among men, smoking decreased from 53.7% in 2000 to 51.3% in 2004 and 49.4% in 2010. Among women, smoking prevalence almost halved between 2000 and 2010.

Diabetes incidence and total mortality {#s3c}
--------------------------------------

Diabetes incidence was estimated using DISMOD based on diabetes prevalence, total mortality, case-fatality and remission rate. The estimated incidence for the year 2004 ranged between 0.002 for those aged 25--34 years to 0.041 and 0.026 for men and women aged 55--64 years and 0.026 for men and 0.011 for women older than 65 years.

Model diabetes prevalence estimates {#s3d}
-----------------------------------

Palestinian diabetes prevalence estimated by the model (for those aged 25 or more) was 9.7% in 2000 (95% CI 7.9% to 11.6%), increasing to 15.3% (95% CI 12.3% to 17.6%) by 2010 ([figure 1](#BMJOPEN2013003558F1){ref-type="fig"}). Diabetes prevalence is predicted to increase rapidly between 2010 and 2020 and then the increase starts to slow down. Prevalence in men increased from 9.1% (95% CI 7.3% to 11.0%) to 16.9% (95% CI 14.6% to 19.4%) and in women from 10.2% (95% CI 8.4% to 12.3%) to 13.6% (95% CI 11.3% to 15.8%).

![Diabetes prevalence forecasting between 2000 and 2030.](bmjopen2013003558f01){#BMJOPEN2013003558F1}

Model validation {#s3e}
----------------

Comparisons of the model estimates with the observed prevalence in the Palestinian Family Health Survey showed a good fit. The observed prevalence was 10.6 versus 11.4% predicted in 2004, 11.8 versus 12.6% in 2006 and 13.8 versus 15.3% predicted using Stepwise survey results.

Diabetes prevalence projections {#s3f}
-------------------------------

The forecasts were 20.6% (95% CI 18.5% to 23.7%) for 2020 and 21.5% (95% CI 20.7% to 25.8%) for 2030.The estimated number of patients with diabetes is expected thus to reach 215 000 in 2015, 289 000 in 2020 and 444 000 in 2030.

Policy scenarios {#s3g}
----------------

If trends in obesity start to decline by 5% starting in 2015, a reduction in diabetes prevalence of 8.3% could be achieved in 15 years (2030). If obesity declined by 10% in 10 years as a realistic target, a 5.3% reduction in diabetes prevalence of 11.1% might be expected. A more ambitious scenario assuming a 15% reduction in 10 years to achieve the WHO target might result in a 11.1%. However, achieving the EMRO-WHO target of a 35% obesity reduction in 10 years could result in 20.2% reduction in diabetes prevalence ([table 2](#BMJOPEN2013003558TB2){ref-type="table"}).

Discussion {#s4}
==========

This paper provides, for the first time, Palestinian-specific future estimates for diabetes prevalence rather than just reporting point prevalence.

The predicted prevalence is worryingly high and is expected to increase by 35% from 2010 to 2020. This is entirely consistent with reports from the IDF.[@R2] The main factor fuelling this increase in diabetes prevalence is the expected continuing increase in obesity prevalence.[@R7] The starting point for obesity prevalence among women is relatively high and is higher than in men. However, men are catching up; their increase overtime is much faster than in women. Although in some countries obesity prevalence increases and then reaches plateau, this phenomenon is not observed in the Palestinian population yet. Hence obesity prevalence forecast was based on the past trend with the assumption of continuous increase.

The estimates of diabetes prevalence calculated from the model were comparable with actual diabetes prevalence measured in the period 2000--2010. The estimates of diabetes prevalence reported in this paper are believed to be more realistic compared with the estimates reported by the IDF and the Global prevalence of diabetes estimates which were critiqued for under estimating the prevalence of diabetes, probably as a result of using only demographic trends and urbanisation as a proxy for diabetes future incidence.[@R1] [@R2] [@R8] By contrast, our model used country-specific trends for diabetes risk factors including obesity and smoking in addition to the demographic trends, whereas the Global Burden of Disease (GBD) used urbanisation as a crude proxy measure for obesity and physical inactivity.[@R2] The estimates of the model and observed diabetes prevalence reported in national surveys were comparable.

We suggest that this model may be appropriate for most low-income and middle-income countries because it is simple, does not require sophisticated statistical software nor huge amounts of specific data. Furthermore, the model can provide estimates for future diabetes prevalence, which can inform policy using different intervention scenarios that can target the specific risk factors included in the model. Several estimates and projections for global or national diabetes prevalence studies are available.

This newly developed model has some limitations. First, models are simplifications of reality, and not all relevant risk factors, such as physical inactivity, were included in the current model. Reliable physical activity level measurements are difficult to obtain in most low-income and middle-income countries. However, the independent contribution of physical inactivity to diabetes incidence is low, suggesting that the impact of policies increasing physical activity levels in any case is likely to be modest. Second, BMI is an imperfect measure of obesity, visceral obesity (WHR) would be preferable, but its availability might not be as widespread as height and weight measurements. Third, limited data were available to estimate obesity trends for the Palestinian population. Having data on obesity for more than two points in time would improve the estimates for obesity trends. The model also assumes a constant incidence rate and case-fatality rates for the projections. These assumptions make the model estimates more conservative, as both will tend to underestimate the size of the prevalence pool. Despite these limitations, the model predictive ability, as compared with observed, independent estimates of diabetes prevalence seems to be good.

Policy scenarios and their importance {#s4a}
-------------------------------------

The paper discusses five population-based intervention policy options and assesses their impact on future diabetes prevalence. Since obesity prevalence is increasing and is predicted to continue to increase, we selected population-based interventions targeting obesity. The Palestinians have a national strategy for preventing the non-communicable diseases. However, this strategy did not set a target for obesity reduction, hence we used WHO, global and regional targets (EMRO), plus two additional targets, one feasible and one ideal. The ambitious targets set by the WHO (a 35% decrease in obesity) would achieve the highest reduction in diabetes prevalence, but might not be feasible. Setting a lower target initially followed by a higher target for longer term might be more realistic. The implementation of the proposed intervention needs to be investigated thoroughly.

Public health implications {#s4b}
--------------------------

The people in Palestine and the Middle East face an increasing prevalence of diabetes. Immediate action is needed to halt this public health disaster. Diabetes can be prevented mainly by policy interventions focusing on obesity reduction. A reduction in calorie intake was reinforced by increased physical activity.[@R9]^--^[@R11] The American Heart Association Council on Epidemiology and Prevention provided an ecological framework for obesity prevention that emphasised the importance of the social, environmental and political context and their powerful influence on the behaviour of families and individuals.[@R12]

Finally, this model has provided reasonably close estimates of diabetes prevalence for oPt over the 2000--2010 period, compared with values observed in contemporary independent surveys in the same population. The model also estimates a worrying increase in the future prevalence of diabetes and this will cause huge economic and healthcare problems.

However, if bold action is now taken, a substantial reduction in the diabetes prevalence and consequently the number of patients with diabetes could still be achieved.
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